Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

BriaCell Therapeutics Corp. (V:BCT)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEDI filings for BCT within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 12, 2019 06:30 ET
BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce its lead product candidate,...
Read full article
Oct 24, 2019 06:30 ET
BriaCell Announces Voting Results of the Special Meeting of Shareholders
BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announced that the shareholders approved all...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.64
--
--
Price to Sales - TTM
--
9.24
8.44
Price to Book - most recent quarter
--
3.48
2.04
Price to Cash Flow per share - TTM
--
--
10.95
Price to Free Cash Flow per share - TTM
--
--
22.44
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Oct 31, 201911,093-207,907
Oct 15, 2019219,00015,777
Sep 30, 2019203,223133,575
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

BriaCell Therapeutics Corp. is a Canada-based immuno-oncology focused biotechnology company developing targeted approaches for the management of cancer. The Company, in collaboration with Incyte Corporation, is conducting a Phase I/IIa clinical trial of Bria-IMT in combination with Incyte drugs, INCMGA00012 and epacadostat, in advanced breast cancer. The Company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and manufacturing logistics associated with other personalized immunotherapies.

See business summary

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).

Twitter

Search (past week) for $BCT.CA BCT.V